European Approval for ROMVIMZA™ Provides Major Boost to Deciphera
Published on 09/18/2025 at 09:45 | Redaktion boerse-global.deDeciphera Pharmaceuticals has achieved a pivotal regulatory victory with the European Commission granting marketing authorization for its drug ROMVIMZA
. The approval, issued on September 17, 2025, covers the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adult patients for whom surgery is not a viable option. This long-awaited decision represents a transformative milestone for the biotechnology firm, which now operates as part of Ono Pharmaceutical.
The authorization is founded on compelling clinical evidence. Study data demonstrated that after 97 weeks, 23% of patients treated with the drug’s active substance, vimseltinib, achieved a complete response. The trial successfully met its primary endpoints at the 25-week mark, showing statistically significant improvements in range... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
